ClinicalTrials.gg
CompletedNCT01329757GHSCIUpdated May 31, 2022

Efficacy and Safety of Growth Hormone Treatment in Spinal Cord Injury

A Phase 3 interventional study of GH and Placebo in Spinal Cord Injury, sponsored by Hospital Nacional de Parapléjicos de Toledo. Completed at 1 site in Spain. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-05-31.

Sponsored by Hospital Nacional de Parapléjicos de Toledo · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies in Spinal Cord Injuries with a site in Spain — 12 open to participants now, 13 under way, 1 of them phase 3. Spinal Cord Injuries · Spain.

Enrollment
9th of 55
76 · median 30
Started
2011
with 1 other
Phase 3
Only one
of the 59
Registered
4th of 59
by date
Lead sponsor
6 of 59
Hospital Nacional de Parapléjicos de Toledo

Among the 59 studies in Spinal Cord Injuries with a site in Spain, this one is the 9th largest by enrollment of the 55 interventional ones that give a count, is one of 2 that started in 2011, is the only one in phase 3, and was the 4th registered.

Spinal Cord Injuries

2,028 studies on the registry are indexed under Spinal Cord Injuries; 540 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

12 of the 59 studies in Spinal Cord Injuries with a site in Spain are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 376 Spinal Cord Injuries studies recruiting now, 167 (44%) set no upper age limit and 158 (42%) stop at 75 or younger; 41 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Spinal Cord Injuries with a site in Spain, or all of them as a file.
02

Study summary

Objectives: To evaluate the efficacy and safety of one year treatment based on daily doses of exogenous growth hormone (GH) in patients with traumatic spinal cord injury. The first six months the pharmacological treatment will be associated to rehabilitation treatment.

The main hypothesis is that GH can improve motor function of patients with traumatic spinal cord injury below the lesion level. The hypothesis is based on possible effects of GH at muscle and synaptic level. GH can also promote axonal growth and regeneration.

Design: Clinical trial placebo-controlled, double-blind intervention with blind evaluation by third parties and blinding in the analysis of data (triple-blind design).

Duration of intervention and monitoring: 364 days.

Primary outcome measures. Changes of the American Spinal Injury Association (ASIA) scale (motor score)

03

Conditions studied

  • Spinal Cord Injury

Keywords

  • Spinal Cord Injury
  • Growth Hormone
  • Trauma
  • Incomplete
  • ASIA
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Traumatic Spinal cord injury
  • Incomplete (ASIA scale B or C)
  • Level of injury: Between C4 and D12
  • More than 18 months from the SCI injury.

Exclusion criteria

Exclusion Criteria:

  • Non traumatic Spinal cord injury
  • Complete SCI (ASIA A)
  • Incomplete (ASIA D or E)
  • Less than 18 months from the SCI
  • Intensive Care Unit (ICU) staying for a period of 2 months or more
  • More than 3 urological infections in the last year
  • Pneumonia in the 6 months prior to the study
  • Severe respiratory failure
  • History of head trauma
  • Severe psychiatric disorder
  • A history of heart disease, diabetes or hypertension
  • Concomitant Neurological Diseases
  • Regular use of substances of abuse
  • Patients with severe kidney and / or liver failure.
  • Patients who can not be included in an intensive rehabilitation program
  • Patients who are pregnant or breast-feeding
  • History of
  • Impossibility to obtain
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
76 participants (actual)

Study arms

  • Active comparator
    GH

    Administration of a daily dose of GH (0.4mg)for 1 year

    Drug: GH

  • Placebo comparator
    Placebo

    Administration of a daily dose of placebo for 1 year

    Drug: Placebo

Interventions

  • DrugGH

    Administration of a subcutaneously injected daily dose of GH (0.4mg)for 1 year

    Also known as: Genotonorm

  • DrugPlacebo

    Administration of a subcutaneously injected daily dose of placebo for 1 year

    Also known as: Provided by the Genotonorm producer (Pfizer)

06

What researchers measure

Primary outcomes

  1. Motor Score of the American Spinal Injury Association (ASIA) scale

    Motor score of the ASIA scale reports the strenght of 10 key muscles in each body side (5 key muscles in upper limb and 5 key muscles in lower limb). The strenght is rated between 0 and 5 (Medical Research Council-MRC scale). The ASIA motor score range is between 0 and 100 (normal).

    Time frame: 12 months

Secondary outcomes

  1. ASIA

    ASIA grades

    Time frame: 12 months

  2. ASIA sensory score

    ASIA sensory score

    Time frame: 12 months

  3. Spasticity

    Penn scale and Ashworth scale

    Time frame: Baseline, 15 days, 6 months, 12 months

  4. Pain

    Visual analogic scale (VAS)

    Time frame: Baseline, 15 days, 6 months, 12 months

  5. Independence Measures and Quality of life

    Spinal Cord Indipendence Measures (SCIM) and the Quality of Life Questionnaire (EQ 5D)

    Time frame: 12 months

  6. Neurophysiological Measures

    Motor Evoked Potentials, Somatosensory Evoked Potentials, Motor Neurography

    Time frame: 6 months and 12 months

  7. Safety

    Recording of any adverse event, full blood and urine examination

    Time frame: 15, 30, 60, 90, 120, 150, 180, 360 days

07

Study locations

1 site
  • Hospital Nacional de Paraplejicos
    Toledo, 45004, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2011 to primary completion in Nov 2015, 55 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2011
First posted
Apr 6, 2011
StartActual
Apr 2011
Primary completionActual
Nov 2015
CompletionActual
Nov 2015
Last update
May 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01329757
Lead sponsor
Hospital Nacional de Parapléjicos de Toledo
Collaborators
Ministerio de Salud y Politicas Sociales (Ministry of Health)
Responsible party
Antonio Oliviero (MD, PhD, Neurologist, Hospital Nacional de Parapléjicos de Toledo) — Principal investigator
First posted
Apr 6, 2011
Start date
Apr 2011
Primary completion
Nov 2015
Completion
Nov 2015
Last update
May 31, 2022

Study contacts

Antonio Oliviero, MD, PhD
principal investigator · Hospital Nacional de Paraplejicos

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion